Radioactive tracer reveals the Body's journey of an experimental drug

NCT ID NCT07764705

Not yet recruiting Knowledge-focused Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This early-stage trial aims to understand how the experimental drug HS-10504 is absorbed, broken down, and eliminated from the body. A small group of healthy adult men will receive a single oral dose of the drug, which is labeled with a radioactive tracer to track its path. By measuring radioactivity in blood, urine, and feces, researchers hope to learn the drug's metabolism and excretion routes, which is essential for future development.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A single oral dose of a radioactively labeled experimental drug called [14C]HS-10504
What this could lead to: If successful, this study could help researchers understand how HS-10504 is processed by the body, which is a key step in developing it as a potential treatment.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. It focuses on drug metabolism, not on whether the drug works for any disease. Results may not predict effectiveness or safety in patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY SUBJECTS

More trials for these conditions

Other studies related to the condition(s) this trial covers.